Document is current
Any future updates will be listed below
-
Authors
Manyazewal, Tsegahun http://orcid.org/0000-0002-8360-7574
Woldeamanuel, Yimtubezinash
Holland, David P.
Fekadu, Abebaw
Marconi, Vincent C.
-
Funding
Funding for this research was provided by:
Fogarty International Center (D43TW009127)
Center for AIDS Research, Emory University (P30 AI050409)
- License Information
-
More Information
Article History
Received: 23 February 2022
Accepted: 9 August 2022
First Online: 28 September 2022
Declarations
:
: The protocol was approved by the Ethiopian Food and Drug Authority (ref. no. 02/25/30/138); the Ethiopian National Research Ethics Review Committee (ref. no MoSHE/RD/4.1/12/07/20); the Institutional Review Board of the College of Health Sciences, Addis Ababa University (ref no. 077/19/CDT); and the Ethical Clearance Committee of the Addis Ababa Health Bureau (ref. no. A/A/H/B/7246/227). All participants provided written informed consent.
: Not applicable.
: V.C.M. has received investigator-initiated research grants (to the institution) and consultation fees (both unrelated to the current work) from Eli Lilly, Bayer, Gilead Sciences, and ViiV. All other authors report no potential conflicts.
